hypo-dolu: an attractive once-weekly

This paper was originally published here, in French. We provide the google translation for your convenience. Proper translation will come soon

hypo-dolu: an attractive once-weekly

Hypo-Dolu: 1/7 truly a very attractive

In ICCARRE 1/7, Dr. Jacques Leibowitch offers a complete lock reverse transcriptase. Beginning in 2015, Dr. Alain Lafeuillade offers maintenance treatment, single dose, weekly, lock integrase.

Alain Lafeuillade offers the following diagram: triple therapy based Tivicay ™ (eg Triumeq ™ or Tivicay ™ + Kivexa ™ or Tivicay ™ + Truvada ™) monitoring Tivicay ™ mono-therapy, then gradual reduction to 1 decision weekly. It seems that the official test to be considered as a first step in Toulon. It also appears that there have been some patients in this process.

The key idea is that dolutegravir (DTG) has little mutation sites that confer resistance, and that, if selected, these mutants have a viability ( 'fitness') so small that it is as if they were gone.

For Hypo-Dolu test, you can inform you here:
Press Release of 20/01/2015 (English)
HYPO-DOLU Lafeuillade HIV HIV treatment dolutegravir Tivicay Hypodolu once-weekly
Personally, I have enough validated my ICCARRE 1/7, and I admit that the proposal of Alain Lafeuillade easier to generalize, easier to swallow, 'and even more economical (at least in France. ..). So I decided to do HYPODOLU way ... This is ongoing, and I am very happy!

Obviously this method will change the perception of therapies weekly catch ... It's going to open the field ... A bit emulation will do good.

Here is the French translation of the press release Hypo-Dolu
January 20, 2015 (MMD Newswire) - Dr. Alain Lafeuillade, MD, PhD, said: The new inhibitor of HIV integrase dolutegravir is a very potent drug not only able to maintain HIV RNA <20 copies / ml in patients naive to treatment or switch patients in monotherapy, but also to maintain control of viral load with 50 mg three times a week, and sometimes twice a week.
Alain Lafeuillade, a clinical researcher for 20 years on HIV, observed that dolutegravir alone is very effective in patients without resistance to integrase. "The viral load remained undetectable in my patients, and proviral HIV DNA into the cells remained stable with only 50 mg 2-3 times a week with an average follow-up of 6 months, adds Dr. Lafeuillade. Therefore he proposed a protocol called "Hypo-Dolu" in HIV patients to determine, in the absence of resistance to integrase inhibitors, the minimum weekly dose of dolutegravir necessary. patients on two reverse transcriptase inhibitors, more dolutegravir 50 mg / day would be spent in dolutegravir mono-therapy for 3 months and then, if the viral load remained <50 copies / mL, will be passed to dolutegravir 50 mg every 2 days, and if the plasma viremia is still contained 50 mg twice a week, then once a week.
"There is hardly any risk of resistance selection, Doctor Lafeuillade added that the single mutation Selectee rarely dolutegravir by the codon 263 of the integrase gene significantly affects the viability of HIV, and that's why dolutegravir healing is tested in trials. Unfortunately, ViiV Healthcare n 'was not interested in the process, preferring to sell its drug at the highest dose, as tested in clinical trials, even if it was too high.

Dr Lafeuillade launch this test as a trial in his institution; he stressed that "in a difficult economic situation, it may be helpful to save medication if a single anti-retroviral triple therapy compared to -By-can do the job at lower doses, and it will also help to save the long-term side effects ".

Contact: Alain Lafeuillade
Head of the Department of Infectious Diseases
General Hospital, 54 rue Henri Sainte-Claire Deville
83100 Toulon, France
Ph: +33 (4) 94 14 50 84
Email: alain.lafeuillade ... then put the at sign, then ... ch-toulon.fr
Complete information is gathered here:
tinyurl.com/CHE-HYPO-DOLU

Several features of dolutegravir and its pharmaceutical form Tivicay ™ justify this approach: we will discuss on this blog. See: Monotherapy Tivicay ® (DTG)




This paper was originally published here, in French. We provide the google translation for your convenience. Proper translation will come soon